Keros Therapeutics, Inc.

KROS

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001664710

SEC filings (opens in a new tab)

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Keros Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of KROS: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Of which not filed for Q2 2024	Q2 2024	Change
Holders	147	1	152	+6
Shares	31.4M	34.2K	31.5M	+131.3K (+0.4%)
Value	$2.08B	$2.26M	$1.44B	−$637.4M (−30.7%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to KROS in Q2 2024
Institution	Shares	Value	% of portfolio
Twinbeech Capital LP	48,988	$2.24M	0.04%
Y-Intercept (Hong Kong) Ltd	38,061	$1.74M	0.10%
PFM Health Sciences, LP	33,355	$1.52M	0.08%
J. Goldman & Co LP	30,102	$1.38M	0.05%
Assenagon Asset Management S.A.	24,459	$1.12M	0.00%
Artia Global Partners LP	20,000	$914.0K	0.23%
ExodusPoint Capital Management, LP	19,940	$911.0K	0.01%
Squarepoint Ops LLC	19,832	$906.3K	0.00%
Point72 (DIFC) Ltd	17,540	$801.6K	0.07%
Corebridge Financial, Inc.	15,852	$724.4K	0.00%
Mirae Asset Global ETFs Holdings Ltd.	15,183	$692.5K	0.00%
Renaissance Technologies LLC	14,300	$653.5K	0.00%
Jump Financial, LLC	13,681	$625.2K	0.01%
SG Americas Securities, LLC	11,633	$532.0K	0.00%
Nebula Research & Development LLC	8,254	$377.2K	0.06%
Dark Forest Capital Management LP	6,355	$290.4K	0.05%
Exchange Traded Concepts, LLC	5,167	$236.1K	0.01%
XTX Topco Ltd	4,996	$228.3K	0.02%
Point72 Asia (Singapore) Pte. Ltd.	2,811	$128.5K	0.03%
Aquatic Capital Management LLC	1,200	$54.8K	0.00%
Innealta Capital, LLC	22	$1.00K	0.00%
CWM, LLC	25	$1.00K	0.00%
SRS Capital Advisors, Inc.	16	$732	0.00%

Sold out (17)

Institutions that held Keros Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of KROS in Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
CIBC World Markets Corp	200,000	$13.2M
HSBC Holdings PLC	46,419	$3.07M
American International Group, Inc.	12,653	$837.6K
Gsa Capital Partners LLP	8,538	$565.0K
FORA Capital, LLC	8,480	$561.4K
Lighthouse Investment Partners, LLC	7,593	$502.7K
Perpetual Ltd	6,689	$442.8K
E Fund Management Co., Ltd.	5,648	$373.9K
Bayesian Capital Management, LP	4,029	$266.7K
Envestnet Asset Management Inc	3,798	$251.4K
LMR Partners LLP	3,671	$243.0K
Pictet Asset Management Holding SA	3,527	$233.5K
Victory Capital Management Inc	3,513	$232.6K
Metropolitan Life Insurance Co	1,353	$89.6K
Riggs Asset Managment Co. Inc.	5	$331
Nelson, Van Denburg & Campbell Wealth Management Group, LLC	4	$264
Principal Securities, Inc.	3	$199

Not filed for Q2 2024 yet (1)

Institutions that held Keros Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KROS in Q1 2024 that haven't filed for Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Credit Suisse AG	34,162	$2.26M